Atherosclerosis in diabetes and insulin resistance

Diabetes, Obesity and Metabolism

Volumn 9, Issue 4, 2007, Pages 455-463

  Reusch, Jane E B ^a,b   Draznin, Boris B ^a,b,c  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Diabetes; Insulin resistance

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VASCULOTROPIN;

ARTERY INTIMA PROLIFERATION; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE COURSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; KINESIOTHERAPY; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; REVIEW; VASCULAR SMOOTH MUSCLE;

EID: 34347385457     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00620.x     Document Type: Review

References (101)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis epidemiology, pathophysiology and management. JAMA 2002; 287: 2570-2581.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorale K, Leakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-334.
3. Ginsberg H. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
4. Rao SV, McGuire D. Epidemiology of diabetes mellitus and cardiovascular disease. In: Marso SP, Stern DM eds. Diabetes and Cardiovascular Disease. Philadelphia: Lippincott Williams & Wilkins, 2004; 153-178.
5. Garg A, Grundy SM. Diabetic dyslipidemia and its therapy. Diabetes Rev 1997; 5: 425-433.
6. Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus (UKPDS 23). BMJ 1998; 316: 823-828.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among U.S. adults: Findings from the third national health and nutrition examination survey. JAMA 2002; 287: 356-359.
8. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 42-46.
9. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005; 54:1615-1625.
10. Amiri F, Venema VJ, Wang X, Ju H, Venema RC, Marrero MB. Hyperglycemia enhances angiotensin II induced janus-activated kinase/STAT signaling in vascular smooth muscle cells. J Biol Chem 1999; 274:32382-32386.
11. Marrero MB, Stern DM. Structure and function of vessel wall. In: Marso SP, Stern DM eds. Diabetes and Cardiovascular Disease. Philadelphia: Lippincott Williams & Wilkins, 2004; 3-17.
12. Nakamura J, Kasuya Y, Hamada Y et al. Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. Diabetologia 2001; 44: 480-487.
13. Ishii H, Koya D, King G. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 2001; 76: 21-31.
14. Srivastava AK. High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: A potential role in the pathogenesis of vascular dysfunction in diabetes. Int J Mol Med 2002; 9: 85-89.
15. Du XL, Edelstein D, Rossetti L et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A. 2000; 97: 12222-12226.
16. Ha H, Lee HB. Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int 2000; 77 (Suppl.): S19-S25.
17. Chappey O, Dosquet C, Wautier MP, Watier JL. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997; 27:97-108.
18. Devaraj S, Vega-Lopez S, Jialal I. Antioxidants, oxidative stress and inflammation in diabetes. In: Marso SP, Stern DM eds. Diabetes and Cardiovascular Disease. Philadelphia: Lippincott Williams & Wilkins, 2004; 19-35.
19. Reaven GM. Insulin resistance and its consequences. In: LeRoith D, Taylor SI, Olefsky JM eds. Diabetes Mellitus. A Fundamental and Clinical Text, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2004; 899-915.
20. Shulman GI. Cellular mechanisms of insulin resistance in humans. Am J Cardiol 1999; 84:3J-10J.
21. Wang CCL, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004; 53:2735-2740.
22. Jiang ZY, Lin YW, Clemont A et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/ fa) rats. J Clin Invest 1999; 104:447-457.
23. Cusi K, Maezono K, Osman A et al. Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105:311-320.
24. Golovchenko I, Goalstone ML, Watson P, Brownlee M, Draznin B. Hyperglycemia enhances transcriptional activity of nuclear factor kB induced by angiotensin II, hyperglycemia, advanced glycosylation end products in vascular smooth muscle cells. Circ Res 2000; 87:746-752.
25. Goalstone ML, Natarajan R, Standley PR et al. Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells. Endocrinology 1998; 139:4067-4072.
26. Samad F, Pandey M, Bell PA, Loskutoff DJ. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Mol Med 2000; 6: 680-692.
27. Nadeau K, Leitner JW, Gurevich I, Draznin B. Insulin regulation of sterol regulatory element-binding protein-1 expression in L-6 muscle cells and 3T3 L1 adipocytes. J Biol Chem 2004; 279:34380-34387.
28. Harada S, Smith RM, Smith JA, White MF, Jarett L. Insulin-induced egr-1 and c-fos expression in 32D cells require insulin receptor, Shc, and mitogen-activated protein kinase, but not insulin receptor substrate-1 and phosphatidylinositol 3-kinase activation. J Biol Chem 1996; 271:30222-30226.
29. Sartpy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003; 100:7265-7270.
30. Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol 1999; 84:21J-24J.
31. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012.
32. Eckel RH, Wassef M, Chait A et al. Prevention conference IV: Diabetes and cardiovascular disease. Writing Group II: Pathogenesis of atherosclerosis in diabetes. Circulation 2002; 105:E138-E143.
33. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001; 108:1341-1348.
34. Hink U, Li H, Mollnau H et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88:E14-E22.
35. Rikitake Y, Liao JK. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cell. Circulation 2005; 111:3261-3268.
36. Giebel SJ, Menucucci G, McGuire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 2005; 85: 597-607.
37. Stary HC, Chandler B, Glagov S et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association. Circulation 1994; 89: 2462-2478.
38. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
39. Detaille D, Guigas B, Chauvin C et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005; 54: 2179-2187.
40. Farhangkhoee H, Khan ZA, Barbin Y, Chakrabarti S. Glucose-induced up-regulation of CD36 mediates oxidative stress and microvascular endothelial cell dysfunction. Diabetologia 2005; 48: 1401-1410.
41. Sheu ML, Ho FM, Yang RS et al. High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler Thromb Vasc Biol 2005; 25: 539-545.
42. Du X, Matsumura T, Edelstein D et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003; 112: 1049-1057.
43. Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 2005; 25: 487-496.
44. Srinivasan S, Hatley ME, Bolick DT et al. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia 2004; 47: 1727-1734.
45. Varma S, Lal BK, Zheng R et al. Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction. Am J Physiol Heart Circ Physiol 2005; 289: H1744-H1751.
46. Ohgami N, Nagai R, Miyazaki A et al. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem 2001; 276: 13348-13355.
47. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE, a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159-1169.
48. Basta G, Lazzerini G, Del Turco S, Ratto GM, Schmidt AM, De Caterina R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol 2005; 25: 1401-1407.
49. Rojas S, Rojas R, Lamperti L, Casanello P, Sobrevia L. Hyperglycaemia inhibits thymidine incorporation and cell growth via protein kinase C, mitogen-activated protein kinases and nitric oxide in human umbilical vein endothelium. Exp Physiol 2003; 88: 209-219.
50. Death AK, Fisher EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: Potential impact on atherosclerosis in diabetes. Atherosclerosis 2003; 168: 263-269.
51. Vogl-Willis CA, Edwards IJ. High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. Biochim Biophys Acta 2004; 1672: 36-45.
52. Kouroedov A, Eto M, Joch H, Volpe M, Luscher TF, Cosentino F. Overexpression of human heme oxygenase-1 attenuates endothelial cell sloughing in experimental diabetes. Am J Physiol Heart Circ Physiol 2004; 287: H2468-H2477.
53. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron A. Obesity/Insulin resistance is associated with endothelial dysfunction. J Clin Invest 1996; 97: 2601-2610.
54. Zeng G, Nystrom FH, Rovichandran LV et al. Roles for insulin receptor, PI 3-kinase, and Akt in insulin signaling pathway related to production of nitric oxide in human vascular endothelial cells. Circulation 2000; 101: 1539-1545.
55. Kuboki K, Jiang ZY, Takahara N et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo. Circulation 2000; 101: 676-681.
56. Kim I, Moon SO, Kim SH, Koh YS, Kho GY. Vascular endothelial growth factor expression of intracellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule (VCAM-1), and E-selectine through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001; 276: 7614-7620.
57. Montagnini M, Golovchenko I, Kim I et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic action of insulin in endothelial cells. J Biol Chem 2002; 277: 1794-1799.
58. LeRoith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001; 24: 588-597.
59. Madonna R, Pandolfi A, Massaro M, Consoli A, De Caterina R. Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia 2004; 47: 532-536.
60. McGill HC Jr, McMahan CA, Zieske AW et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 2000; 20: 1998-2004.
61. McGill HC Jr, McMahan CA, Herderick EE et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002; 105: 2712-2718.
62. Renard CB, Kramer F, Johansson F et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 2004; 114: 659-668.
63. Lamharzi N, Renard CB, Kramer F et al. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: Potential role of glucose-oxidized LDL. Diabetes 2004; 53: 3217-3225.
64. Kornerup K, Nordestgaard BG, Feldt-Rasmussen B, Borch-Johnsen K, Jensen KS, Jensen JS. Increased transvascular low density lipoprotein transport in insulin dependent diabetes: A mechanistic model for development of atherosclerosis. Atherosclerosis 2003; 170: 163-168.
65. Schmidt AM, Vianna M, Gerlach M et al. Isolation and characterization of binding proteins for advanced glycosylation end products from lung tissue which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-14997.
66. Wendt T, Harja E, Bucciarelli L et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006; 185: 70-77.
67. Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 1998; 4: 1025-1031.
68. Horiuchi S, Unno Y, Usui H et al. Pathological roles of advanced glycation end product receptors SR-A and CD36. Ann N Y Acad Sci 2005; 1043: 671-675.
69. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 1995; 75: 487-517.
70. Wang CCL, Gurevich I, Draznin B. Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes 2003; 52: 2562-2569.
71. Schultz K, Rusmussen LM, Ledet T. Expression levels and functional aspects of the hyaluronan receptor CD44. Effects of insulin, glucose, IGF-I, or growth hormone on human arterial smooth muscle cells. Metabolism 2005; 54: 287-295.
72. Li H, Telemaque S, Miller RE, Marsh JD. High glucose inhibits apoptosis induced by serum deprivation in vascular smooth muscle cells via upregulation of Bcl-2 and Bcl-xl. Diabetes 2005; 54: 540-545.
73. Shimizu H, Toyama O, Shiota M, Kim-Mitsuyama S, Miyazaki H. Protein tyrosine phosphatase LMW-PTP exhibits distinct roles between vascular endothelial and smooth muscle cells. J Recept Signal Transduct Res 2005; 25: 19-33.
74. Klemm DJ, Watson PA, Frid MG et al. CREB content is a molecular determinant of smooth muscle cell proliferation and migration. J Biol Chem 2001; 276: 46132-46141.
75. Watson PA, Nesterova A, Burant C, Klemm DJ, Reusch JE-B. Diabetes-related changes in CREB content enhance smooth muscle cell proliferation and migration. J Biol Chem 2001; 276: 46142-46150.
76. Suzuki LA, Poot M, Gerrity RG, Bornfeldt KE. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: Lack of direct growth-promoting effects of high glucose levels. Diabetes 2001; 50: 851-860.
77. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412.
78. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-967.
79. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987; 36: 689-692.
80. Nathan DM, Lachim J, Cleary P et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-2303.
81. The DCCT Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.
82. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999; 99: 2626-2632.
83. Lazar HL, Chipkin SR, Fitzgerald DA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004; 109: 1497-1502.
84. Malmberg K, Ryden L, Wedel H et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J 2005; 26: 650-661.
85. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
86. Sundquist K, Quist J, Sunquist J, Johansson SE. Frequent and occasional physical activity in the elderly: A 12-year follow-up study of mortality. Am J Prev Med 2004; 27: 22-27.
87. Gregg EW, Gerzoff RB, Caspersen CJ, Williamson DF, Narayan KM. Relationship of walking to mortality among US adults with diabetes. Arch Intern Med 2003; 163: 1440-1447.
88. Maiorana A, O'Driscoll G, Cheetham C et al. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J Am Coll Cardiol 2001; 38: 860-866.
89. Esposito K, Pontillo A, Di Palo C et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA 2003; 289: 1799-1804.
90. Walther C, Gielen S, Hambrecht R. The effect of exercise training on endothelial function in cardiovascular disease in humans. Exerc Sport Sci Rev 2004; 32: 129-134.
91. Wei C, Penumetcha M, Santanam N, Liu YG, Garelnabi M, Parthasarathy S. Exercise might favor reverse cholesterol transport and lipoprotein clearance: Potential mechanism for its anti-atherosclerotic effects. Biochim Biophys Acta 2005; 1723: 124-127.
92. Ramachandran S, Penumetcha M, Merchant NK, Santanam N, Rong R, Parthasarathy S. Exercise reduces preexisting atherosclerotic lesions in LDL receptor knock out mice. Atherosclerosis 2005; 178: 33-38.
93. Avena R, Mitchell ME, Nylen ES, Curry KM, Sidawy AN. Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg 1998; 28: 1024-1031.
94. Yoshimoto T, Naruse M, Shizume H et al. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 1999; 145: 333-340.
95. Collins AR, Meehan WP, Kintscher U et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 365-371.
96. Chinetti G, Lestavel S, Bocher V et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53-58.
97. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930-934.
98. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
99. Nakamura T, Matsuda T, Kawagoe Y et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004; 53: 1382-1386.
100. Choi D, Kim SK, Choi SH et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654-2660.
101. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 2003; 92: 34J-41J.